Restructuring And AI Trials Will Advance Spinal Cord Stimulation
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
03 Apr 25
Updated
03 Apr 25
AnalystConsensusTarget's Fair Value
US$6.53
10.6% undervalued intrinsic discount03 Apr
US$5.84
1Y
-56.1%7D
0%